Fiscal Impact: Plans would be required to provide continuous prescription drug coverage for a previously covered chronic medication to medically stable enrollees without the ability to change the patient cost share or direct patients to more cost effective alternatives in a plan year. This requirement may lead to a fiscal impact through three possible mechanisms. First, the price of multi-source drugs can fluctuate greatly during a plan year depending on unpredictable market forces that influence supply and demand. The inability to direct enrollees to less expensive but therapeutically equivalent alternatives would impair cost-effective management of plan formularies. Second, SB6147 would force plans to cover more expensive brand name products with the same level of patient cost sharing prior to the availability of a new generic equivalent. Lastly, the plans could also lose rebates associated with single-sourced brand name drugs. Rising prescription drugs costs due to the fiscal impacts cited above may result in increased premiums for plan enrollees. The financial cost of this legislation is estimated at $3,437,906 between 2017-2019, $6,859,652 between 2019-2021, and $6,859,6522 between 2021-2023.